Top Talent Acquisition PepGen Inc has recently made strategic hires, bringing in experienced professionals like Michelle Mellion as Senior Vice President, Global Regulatory Affairs, and Paul Streck as Executive Vice President, Head of Research & Development. Leveraging this top talent can open doors for collaborations and partnerships.
Enhanced Delivery Platform With a proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is developing disease-modifying therapeutics for genetic neuromuscular and neurological disorders. Highlighting the unique benefits and effectiveness of this platform can attract interest from potential investors and pharmaceutical companies looking for innovative solutions.
Strategic Board Additions The recent addition of Christopher Ashton, PhD, to the Board of Directors brings valuable expertise to PepGen. Utilizing Ashton's experience can help in building credibility and trust with key stakeholders, potentially leading to opportunities for licensing deals or research collaborations.
Financial Stability and Growth PepGen's solid financials, with revenue in the range of $10M - $50M and total funding of $158M, indicate a stable foundation for business expansion. Positioning the company as financially secure can attract potential investors or acquisition offers.
Market Presence and Competitive Landscape Being part of the biotechnology research industry alongside companies like Vertex Pharmaceuticals and Sarepta Therapeutics, PepGen has the opportunity to differentiate itself through its unique technology and pipeline. Identifying gaps in the market and showcasing competitive advantages can help in capturing market share and securing strategic partnerships.
6.1K
$1B
1.5K$100M$1B
82$10M$50M
105$10M$50M
507$100M$1B
69$10M$50M
132$10M$50M
29
174$10M$50M
139$10M$50M
27PepGen uses 8 technology products and services including JazzHR, Adobe Fonts, Font Awesome, and more. Explore PepGen's tech stack below.
| PepGen Email Formats | Percentage |
| FLast@pepgen.com | 49% |
| First@pepgen.com | 1% |
| FirstLast@pepgen.com | 1% |
| FLast@pepgen.com | 49% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.
Company Overview
Media & News
Funding & FinancialsPepGen has raised a total of $158M of funding over 2 rounds. Their latest funding round was raised on Aug 05, 2021 in the amount of $113Mas a crossover financing.
PepGen's revenue is in the range of $10M$50M
Funding & FinancialsPepGen has raised a total of $158M of funding over 2 rounds. Their latest funding round was raised on Aug 05, 2021 in the amount of $113Mas a crossover financing.
PepGen's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com